Table 1.
Baseline clinical characteristics.
| Characteristic | Group I (n = 256) | Group II (n = 370) | Group III (n = 293) | |
|---|---|---|---|---|
| Sex | ||||
| Male | 149 (58%) | 198 (54%) | 171 (58%) | |
| Female | 107 (42%) | 172 (46%) | 122 (42%) | |
| Age of diagnosis (months) | ||||
| Median | 20 | 15 | 23 | |
| Range | 1–117 | 0–119 | 2–60 | |
| Laterality | ||||
| Unilateral | 161 (63%) | 211 (57%) | 291 (99%) | |
| Bilateral | 95 (37%) | 159 (43%) | 2 (1%) | |
| Follow-up Time (months) | ||||
| Median | 70 | 62 | 77 | |
| Range | 2–103 | 0–101 | 0–102 | |
| Lost to follow-up | 5 (2%) | 89 (24%) | 28 (10%) | |
| IIRC of Studied Eye | ||||
| A | 1 (0.4%) | 17 (5%) | 0 (0%) | |
| B | 8 (3%) | 47 (13%) | 0 (0%) | |
| C | 15 (6%) | 15 (4%) | 0 (0%) | |
| D | 180 (70%) | 198 (53%) | 114 (39%) | |
| E | 52 (20%) | 89 (24%) | 151 (51%) | |
| Unknown | 0 (0%) | 4 (1%) | 28 (10%) | |
| Enucleation | ||||
| No | 204 (80%) | 195 (53%) | 0 (0%) | |
| Yes | 52 (20%) | 175 (47%) | 293 (100%) | |
| AJCC Histopathology | ||||
| pT1 | 20 (38%) | 117 (67%) | 146 (50%) | |
| pT2 | 10 (19%) | 7 (4%) | 23 (8%) | |
| pT3 | 14 (27%) | 18 (10%) | 68 (23%) | |
| pT4 | 6 (12%) | 10 (6%) | 10 (3%) | |
| Unknown | 2 (4%) | 23 (13%) | 46 (16%) | |